Eisai Pharmaceuticals Launches Operations in Saudi Arabia to Enhance Patient Care in Critical Fields
Riyadh, Saudi Arabia, October 5, 2025: Eisai EMEA, a subsidiary of Eisai Co. Ltd. the global leader in research-based pharmaceuticals headquartered in Tokyo, Japan, has announced the inauguration of its new official branch in Riyadh. This step marks a significant strategic expansion in the Kingdom and the Middle East region.
This expansion reflects the company’s commitment to serving patients in Saudi Arabia across several critical fields, including insomnia, oncology, and Alzheimer’s disease—areas where there remains a pressing need for innovative solutions due to the increasing burden of these conditions.
The inauguration ceremony was attended by many prominent figures, led by Mr. Haruo Naito, Representative Corporate Officer, whose presence underscored the importance and strategic dimension of the event. Mr. Morino Yasunari’s the Japanese ambassador. In addition to Mr. Gary Hendler, Chairman and CEO of Eisai Europe, along with several vice presidents and Eisai Saudi Arabia Directors. The event was further honored by the presence of the Japanese Ambassador to Saudi Arabia, reflecting the depth and strength of economic relations between the two countries.
The launch of Eisai Saudi Arabia embodies the company’s commitment to serving patients in the Kingdom and meeting the growing medical needs in critical therapeutic areas. The new branch will play a pivotal role in supporting Saudi Vision 2030 and the Health Sector Transformation Program, which aims to improve access to and quality of healthcare and foster innovation through public-private partnerships.
Eisai Saudi Arabia begins its operations in tandem with the introduction of pioneering medications for insomnia, Alzheimer’s disease management in addition to established medications in oncology and neurology reflecting the company’s dedication to providing innovative solutions and actively contributing to the development of the healthcare system in the Kingdom.
On this occasion, the Japanese ambassador Mr. Morino Yasunari’s, remarked “The establishment of Eisai new office in Riyadh, Saudi Arabia, represents a significant step forward in contributing to the medical and health sectors in this region”
For his part, Mr. Gary Hendler, Chairman and CEO of Eisai Europe and Head of the Europe, Middle East, and Africa region, emphasized that the Saudi market is among the company’s top strategic priorities, highlighting Eisai’s unwavering commitment to supporting Vision 2030 by providing innovative treatments and building strong partnerships to help improve patient outcomes.
It is noteworthy that Eisai Saudi Arabia’s operations will be based on a patient-centric approach, with every initiative guided by the real needs of patients and healthcare providers, in line with the hhc philosophy.
The new branch will also work closely with medical communities and regulatory authorities to ensure effective access to treatments and make a tangible impact on quality of life, as Eisai believes that understanding the patient’s experience is fundamental to delivering meaningful healthcare solutions.
End
